The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

BTOG 2021 | Patient perspective: UK approval of first-line brigatinib

Name: Patient perspective: UK approval of first-line brigatinib
Uploaded: 2021-04-19T00:00:00Z
Duration: 1 min 44 s
Description: Debra Montague, Founder & Chairman, ALK Positive UK, discusses the NICE approval of brigatinib in the first line in the UK for the treatment of patients with ALK-positive lung cancer who have previously been treated with an ALK inhibitor. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.

Debra Montague • 19 Apr 2021

BTOG 2021

Lung Cancer Non-Small Cell Lung Cancer Brigatinib

Debra Montague, Founder & Chairman, ALK Positive UK, discusses the NICE approval of brigatinib in the first line in the UK for the treatment of patients with ALK-positive lung cancer who have previously been treated with an ALK inhibitor. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.